1. Agarwal A, Gupta V, Brahmbhatt P, Desai A, Vibhute P, Joseph-Mathurin N, et al. Amyloid-related imaging abnormalities in Alzheimer disease treated with anti–amyloid-β RadioGraphics. 2023;43(9):e230205. doi:10.1148/rg.230205
2. Cogswell PM, Barakos JA, Barkhof F, Benzinger TS, Jack CR Jr, Poussaint TY, et al. Amyloid-related imaging abnormalities with emerging Alzheimer disease therapeutics: Detection and reporting recommendations for clinical practice. AJNR Am J Neuroradiol. 2022;43(9):E19–E35. doi:10.3174/ajnr.A7586.
3. Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities: Radiological, biological and clinical characteristics. 2023;146(11):4414–24. doi:10.1093/brain/awad188.
4. Cummings J, Osse AML, Cammann D, Powell J, Chen J. Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease. 2024;38(1):5–22. doi:10.1007/s40259-023-00633-2.
5. Cummings J, Aisen P, Apostolova LG, Atri A, Salloway S, Weiner M. Aducanumab: Appropriate Use Recommendations. J Prev Alzheimers Dis. 2021;8(4):398-410. doi:10.14283/jpad.2021.41.
6. Withington CG, Turner RS. Amyloid-related imaging abnormalities with anti-amyloid antibodies for the treatment of dementia due to Alzheimer’s disease. Front Neurol. 2022;13:862369. doi:10.3389/fneur.2022.862369.
7. Roytman M, Mashriqi F, Al-Tawil K, Schulz PE, Zaharchuk G, Benzinger TLS, et al. Amyloid-related imaging abnormalities: An update. AJR Am J Roentgenol. 2023;220(4):562–575. doi:10.2214/AJR.22.28461.